INTCO MEDICAL(300677)2025-04-28 11:55Financial Performance - The company's revenue for Q1 2025 reached ¥2,493,933,645.56, representing a 13.20% increase compared to ¥2,203,087,168.00 in the same period last year[4] - Net profit attributable to shareholders was ¥352,721,895.21, up 48.08% from ¥238,197,783.00 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 53.22%, amounting to ¥246,606,613.51 compared to ¥160,950,736.00 in the previous year[4] - Basic earnings per share rose to ¥0.55, a 52.78% increase from ¥0.36 in the previous year[4] - Net profit for the current period was ¥361,372,917.73, representing a significant increase of 50.2% from ¥240,565,774.00 in the previous period[21] - Basic and diluted earnings per share increased to 0.55 from 0.36, representing a growth of 52.78% year-over-year[22] Cash Flow - The net cash flow from operating activities surged by 150.73%, totaling ¥406,102,817.23, compared to ¥161,970,968.00 in the same period last year[4] - Operating cash inflow totaled approximately ¥2.72 billion, up from ¥2.40 billion, reflecting an increase of 13.43%[23] - Total cash outflow for operating activities was approximately ¥2.31 billion, compared to ¥2.24 billion in the previous period, an increase of 3.23%[23] - Cash flow from investing activities showed a net outflow of ¥2.26 billion, a decline from a net inflow of ¥682.93 million in the prior period[24] - Cash flow from financing activities generated a net inflow of approximately ¥2.63 billion, compared to ¥2.23 billion in the previous year, indicating an increase of 18.14%[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥37,286,999,455.90, reflecting a 7.67% increase from ¥34,630,896,412.44 at the end of the previous year[4] - Current liabilities rose to ¥16,932,585,772.68, up from ¥14,682,518,276.02, indicating an increase of 15.3%[18] - Non-current liabilities totaled ¥2,312,364,439.73, slightly up from ¥2,266,697,098.47, reflecting a growth of 2.0%[18] - The company's total equity increased to ¥18,042,049,243.49, compared to ¥17,681,681,037.95, showing a growth of 2.0%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 61,786[10] - The largest shareholder, Liu Fangyi, holds 35.86% of the shares, amounting to 231,703,107 shares, with 7,650,000 shares pledged[10] - The company reported a total of 177,081,960 shares subject to lock-up at the end of the period, down from 177,152,329 shares, a reduction of about 0.04%[13] - The company has not disclosed any changes in the top 10 shareholders due to margin trading activities[12] - The company has not identified any related party relationships among the top shareholders[13] Other Financial Metrics - The company reported non-recurring gains of ¥106,115,281.70, primarily from government subsidies and fair value changes of financial assets[6] - Research and development expenses for the current period were ¥99,551,616.56, compared to ¥84,578,719.00, an increase of 17.7%[21] - The company reported a financial income of ¥131,053,333.02, up from ¥99,403,769.00, reflecting a growth of 32.0%[21] - Other comprehensive income after tax was -¥5,676,841.42, compared to ¥3,370,903.00 in the previous period, indicating a decline[21] Cash and Investments - The company's cash and cash equivalents decreased to ¥11,818,079,821.89 from ¥12,014,011,946.78, reflecting a decline of approximately 1.63%[16] - Trading financial assets increased significantly to ¥9,167,759,033.53 from ¥6,737,459,715.11, marking a growth of about 36.93%[16] - Accounts receivable rose to ¥1,437,681,488.31 from ¥1,362,747,313.74, indicating an increase of approximately 5.49%[16] - The company’s prepayment items increased to ¥222,986,278.24 from ¥204,297,475.65, reflecting a growth of approximately 9.00%[16] - The company’s other receivables increased to ¥93,649,636.68 from ¥78,326,027.38, showing an increase of about 19.53%[16]